Market Overview

UPDATE: JP Morgan Reiterates Baxter International at Overweight; Gambro Expensive but Worth It

Related BAX
Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
Merck Snags Baxter Executive As CFO (Fox Business)

JP Morgan reiterated its Overweight rating on Baxter International (NYSE: BAX) along with its previous $48 price target.

JP Morgan said, "A $4B purchase price would value Gambro at 2.4x 2011 sales and 12.7x 2011 EBITDA. Extrapolating off the 9 month numbers for 2012 gets you to 2.5x 2012 Revs and 16.3x EBITDA, though again this includes the impact of the Italian quake. By comparison, Baxter trades at 9.7x 2013E EBITDA, with slower growth peers trading at 7-8x. … That said, a Gambro acquisition would (a) allow Baxter to utilize its OUS cash and (b) given the interest currently being earned on this cash and the cost to borrow, the deal would on a cash basis almost certainly be accretive, despite the price tag. It would obviously change in a significant way Baxter's presence in the hemodialysis market, complementing its current leadership in peritoneal dialysis."

Baxter International closed at $58.43 on Friday.

Latest Ratings for BAX

DateFirmActionFromTo
Oct 2014BarclaysMaintainsOverweight
Oct 2014Credit SuisseMaintainsOutperform
Oct 2014Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (BAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional